1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Four Offerings In One Week As Biopharma Keeps Its IPO Market Lead

 
• By Mandy Jackson

Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals. 

Finance Watch

Biopharmaceutical companies continued their domination of the market for initial public offerings during the week of 8-12 June with IPOs from Avidity Biosciences Inc., Generation Bio Co., Vaxcyte Inc. and Lantern Pharma Inc. – four drug developers, plus the Chinese diagnostics firm Burning Rock Biotech, in a week when only eight companies went public in the US. 

Biopharma has been one of the leading industries for IPOs during the past few years and the pace slowed only for a few weeks with the pandemic as stock valuations sank more than 30% from the start of the year. By April, drug developers started to launch IPOs again, including ORIC Pharmaceuticals Inc., as biopharma stock price gains outpaced the performance of other companies in other industries

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic

 
• By Mandy Jackson

HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.